구충제 시장 : 약물 유형별, 감염 유형별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

Anthelmintic Drugs Market By Drug Class, By Infection Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,004,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,410,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

구충제 시장은 제약 분야 시장 수요 증가로 인해 2023년부터 2032년까지 3.8%의 높은 성장률을 나타낼 것으로 보입니다.

구충제는 전 세계 수백만 명이 앓고 있는 기생충 감염의 세계적 확산으로 인해 전 세계 보건 활동에서 중요한 역할을 하고 있습니다. 이러한 감염은 선충, 편충, 회충에 의해 발생하며, 특히 위생 상태가 열악하고 의료 서비스 접근성이 낮은 국가에서 많이 발생합니다. 많은 개발도상국에서는 다음과 같은 토양전염성(STH) 기생충이 널리 퍼져 있습니다.

1 회충, 편충, 구충이 유행하고 있습니다. 이러한 감염은 특히 어린이에게 심각한 건강 문제를 일으켜 성장, 인지 및 삶의 질에 영향을 미칠 수 있습니다.

예를 들어, 2021년 국립생물공학정보센터(NCBI)가 발표한 논문에 따르면, 전 세계적으로 약 350만 명이 장내 기생충 감염으로 인해 연간 20만 명 이상이 사망하는 것으로 보고되고 있습니다. 이러한 기생충 감염증의 발생은 구충제의 필요성을 높이고 있으며, 시장 성장을 가속하고 있습니다. 또한, 동물에서 사람에게 감염되어 다음과 같은 심각한 건강 문제를 일으키는 인수공통전염병도 있습니다.

1 촌충의 합병증인 무좀. 이러한 감염병을 퇴치하는 것은 개개인의 이익뿐만 아니라 지역사회의 복지에 기여하고 경제 생산성을 높이며 삶의 질을 향상시키는 데에도 도움이 됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 구충제 시장 : 약제 클래스별

• 개요
• Benzimidazoles
• Macrocyclic Lactones
• Pyrazinoisoquinolones
• Tetrahydropyrimidines
• 기타

제5장 구충제 시장 : 감염 유형별

• 개요
• 조충 감염
• 선충 감염
• 흡충 감염
• 혼합 감염

제6장 구충제 시장 : 유통 채널별

• 개요
• 병원 약국
• 드럭스토어 및 소매 약국
• 온라인 공급업체

제7장 구충제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카/중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Reese Pharmaceutical Company
• Amneal Pharmaceuticals LLC
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Bayer AG
• Cipla Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Limited
• Zydus Lifesciences Limited

LSH

영문 목차

영문목차

The anthelmintic drugs market is likely to experience a significant growth rate of 3.8% from 2023-2032 owing to increasing market demand from pharmaceuticals sector - Allied Market Research

Anthelmintic drugs play an essential role in global health initiatives due to the global prevalence of parasitic worm infections, which affect millions of people around the globe. These infections are caused by nematode, trematode, and cestode, and are particularly prevalent in countries with poor sanitation and lack of access to healthcare. In many developing countries, soil-transmitted (STH) helminths such as roundworm, whipworm, and hookworm are endemic. These infections cause serious health problems, particularly in children, which can affect their growth, cognition, and quality of life.

For instance, according to an article published by National Centre for Biotechnology Information (NCBI) in 2021, globally there are around 3.5 million people affected with intestinal parasitic infections, and more than 200,000 deaths are reported annually. Such incidences of such parasitic infections are increasing the need for anthelmintic, which propels the market growth. In addition, there are also zoonotic infections, which are transmitted by animals to humans and can lead to serious health problems, such as hydatid disease which is a complication of the tapeworm. Combating these infections not only benefits the individual, but also contributes to the well-being of the community, increases economic productivity, and improves the quality of life.

In addition, there is an increase in government expenditure and investment in healthcare infrastructure, including the allocation of funds to treat and prevent various diseases, such as parasitic worm infections, owing to economic growth in emerging economies. There is an increase in availability of affordable and accessible anthelmintic drug for the population owing to increased financial resources for healthcare. Economic growth often leads to improved access to healthcare facilities, such as clinics, hospitals and pharmacies. This improved accessibility means that people living in rural or poor areas, where the prevalence of parasitic infections may be higher, can now visit healthcare facilities to be diagnosed and treated for these conditions. The demand for anthelmintic drugs increases as more people can access healthcare facilities.

The anthelmintic drugs market is segmented on the basis of drug class, infection type, distribution channel, and region. On the basis of drug class, the market is divided into benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines and others. On the basis of infection type, the market is classified into nematode infections, cestode infections, trematode infections and mixed infections. Based on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.

Major players profiled in this report are GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Bayer AG, Cipla Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Reese Pharmaceutical Company, and Zydus Lifesciences Limited.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anthelmintic drugs market analysis from 2022 to 2032 to identify the prevailing anthelmintic drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the anthelmintic drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global anthelmintic drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Drug Class

• Benzimidazoles
• Macrocyclic Lactones
• Pyrazinoisoquinolones
• Tetrahydropyrimidines
• Others

By Infection Type

• Cestode Infections
• Nematode Infections
• Trematode Infections
• Mixed Infections

By Distribution Channel

• Online Providers
• Hospital Pharmacies
• Drug Stores and Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• GlaxoSmithKline plc
• Johnson & Johnson
• Cipla Ltd.
• Teva Pharmaceutical Industries Limited
• Zydus Lifesciences Limited
• Amneal Pharmaceuticals LLC
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Reese Pharmaceutical Company
• Bayer AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rising incidences of parasitic infections
    • 3.4.1.2. Growing awareness of preventive measures against helminth infections
    • 3.4.1.3. Availability of generic medications
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of anthelmintic drugs
    • 3.4.2.2. Lack of awareness and education about infectious diseases
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth opportunities in emerging markets

CHAPTER 4: ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Benzimidazoles
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Macrocyclic Lactones
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Pyrazinoisoquinolones
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Tetrahydropyrimidines
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Others
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Cestode Infections
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Nematode Infections
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Trematode Infections
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Mixed Infections
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Stores and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: ANTHELMINTIC DRUGS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Drug Class
  • 7.2.3. Market size and forecast, by Infection Type
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Drug Class
    • 7.2.5.1.2. Market size and forecast, by Infection Type
    • 7.2.5.1.3. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Drug Class
    • 7.2.5.2.2. Market size and forecast, by Infection Type
    • 7.2.5.2.3. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Drug Class
    • 7.2.5.3.2. Market size and forecast, by Infection Type
    • 7.2.5.3.3. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Drug Class
  • 7.3.3. Market size and forecast, by Infection Type
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Drug Class
    • 7.3.5.1.2. Market size and forecast, by Infection Type
    • 7.3.5.1.3. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Drug Class
    • 7.3.5.2.2. Market size and forecast, by Infection Type
    • 7.3.5.2.3. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Drug Class
    • 7.3.5.3.2. Market size and forecast, by Infection Type
    • 7.3.5.3.3. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Drug Class
    • 7.3.5.4.2. Market size and forecast, by Infection Type
    • 7.3.5.4.3. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Drug Class
    • 7.3.5.5.2. Market size and forecast, by Infection Type
    • 7.3.5.5.3. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Drug Class
    • 7.3.5.6.2. Market size and forecast, by Infection Type
    • 7.3.5.6.3. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Drug Class
  • 7.4.3. Market size and forecast, by Infection Type
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Drug Class
    • 7.4.5.1.2. Market size and forecast, by Infection Type
    • 7.4.5.1.3. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Drug Class
    • 7.4.5.2.2. Market size and forecast, by Infection Type
    • 7.4.5.2.3. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Drug Class
    • 7.4.5.3.2. Market size and forecast, by Infection Type
    • 7.4.5.3.3. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Drug Class
    • 7.4.5.4.2. Market size and forecast, by Infection Type
    • 7.4.5.4.3. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Drug Class
    • 7.4.5.5.2. Market size and forecast, by Infection Type
    • 7.4.5.5.3. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Drug Class
    • 7.4.5.6.2. Market size and forecast, by Infection Type
    • 7.4.5.6.3. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Drug Class
  • 7.5.3. Market size and forecast, by Infection Type
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Drug Class
    • 7.5.5.1.2. Market size and forecast, by Infection Type
    • 7.5.5.1.3. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Drug Class
    • 7.5.5.2.2. Market size and forecast, by Infection Type
    • 7.5.5.2.3. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Drug Class
    • 7.5.5.3.2. Market size and forecast, by Infection Type
    • 7.5.5.3.3. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Drug Class
    • 7.5.5.4.2. Market size and forecast, by Infection Type
    • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Reese Pharmaceutical Company
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
• 9.2. Amneal Pharmaceuticals LLC
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. GlaxoSmithKline plc
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. Johnson & Johnson
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. Merck & Co., Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Bayer AG
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Cipla Ltd.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Sun Pharmaceutical Industries Ltd.
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Teva Pharmaceutical Industries Limited
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Zydus Lifesciences Limited
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료